Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Quality Profiling: Agency Hopes to Channel Corporate Attention (And Money) To Quality Systems

This article was originally published in RPM Report

Executive Summary

FDA’s drug compliance leadership sees new risk assessment authority for setting inspection schedules from FDASIA as an appealing foundation for collecting and preparing profiles of drug manufacturers. Just don’t call them “report cards.”

Advertisement

Related Content

FDA’s Metric System: Quality Scores Are High Priority For Agency, But Industry Concerns Keep Pace Slow
FDA’s Generic Drug Manufacturer Inspections Under OIG Review
FDA’s Call for Quality: Revamped GMP Initiative Stresses Cost Savings
FDA’s Call for Quality: Revamped GMP Initiative Stresses Cost Savings
Door-Opener for Inspections: Guidance Lists Unacceptable Tactics To Hamper FDA Visits
FDA Could Release GMP Data To Prod Manufacturing Improvements

Topics

Advertisement
UsernamePublicRestriction

Register

PS081161

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel